MedPath

To Evaluate Safety and Efficacy of Pathadi Ghanavati and Pathadi Oil in Psoriasis

Phase 2
Recruiting
Conditions
Psoriasis, unspecified. Ayurveda Condition: KITIBAH,
Registration Number
CTRI/2021/12/038806
Lead Sponsor
HON SHRI ANNASAHEB DANGE AYURVED MEDICAL COLLEGE AND POSTGRADUATE CENTER ASHTA SANGLI
Brief Summary

Psoriasis is common dermatological disease affecting up to 0.09 to 11.4 % of world’s population and approximately 3% of Indian population. It is a chronic inflammatory, non communicable, disfiguring and disabling disease. It involves the skin, nails and is associated with a number of co morbidities. Psoriasis originates from the Greek word “Psora†that means “itchâ€.  It occurs mostly in second and fourth decade of life and affects male and female equally. The skin is largest organ of the body and is considered as “Organ of expressionâ€. Due to disfiguring, psoriasis has a negative effect on the daily life, self confidence and self esteem. The prevalence of the psoriasis in India is increasing day by day. Increasing prevalence and its association with various co morbidities affects quality of life of patients suffering from psoriasis. So there is a need for research on various aspects such as epidemiology, etio- pathogenesis, and management. There is a large gap addressing the therapeutic aspects of the psoriasis where there is no definitive curative therapy available. Ayurveda Medicines has shown considerable effects in the Psoriasis. Thus, the present study is undertaken to evaluate efficacy of Pathadi Ghanavati and Pathadi Oil in the management of Kitibha (Psoriasis). 50 patients who are having signs and symptoms of Psoriasis as mentioned in inclusion criteria will be selected and treated with Pathadi Ghanavati internally and Pathadi Oil external application for 30 days. Assessment will be done on the basis of percentage relief in signs and symptoms of the Psoriasis. The reduction in mean score of Simplified Psoriasis Area and Severity Index, Physician’s Global Assessment Scale, Physician’s Global Assessment Scale and Body Surface Area Scale and Improvement in Dermatology Life Quality Index. Appropriate statistical tests will be applied to test the significance. Diet will be advised according to physical constitution or Prakriti to prevent recurrence of the disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
50
Inclusion Criteria

1.Patients who are having sign and symptoms of Psoriasis 2.Patients suffering from psoriasis with less than 50% of the body surface involvement.

Exclusion Criteria
  • 1.Pregnant and lactating mothers 2.Patients having any severe systemic disorders like Diabetes Mellitus, Cancer etc.
  • 3.Patients suffering from psoriasis with more than 50% of the body surface involvement and with other co morbidities.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Improvement in Dermatology Life Quality Index(DLQI)7th Day, 14th Day,21th Day,30th Day
2. Improvement in Signs and Symptoms of Psoriasis7th Day, 14th Day,21th Day,30th Day
Secondary Outcome Measures
NameTimeMethod
1. Reduction in mean Simplified Psoriasis Area and Severity Index Score (SPASI)2. Reduction in mean Physicians Global Assessment Scale Score (PGA)

Trial Locations

Locations (2)

Hon Shri Annasaheb Dange Ayurved Medical College and Postgraduate Research Center,Ashta,Sangli

🇮🇳

Sangli, MAHARASHTRA, India

Dr D Y Patil College of Ayurved and Research Center, Pimpari, Pune

🇮🇳

Pune, MAHARASHTRA, India

Hon Shri Annasaheb Dange Ayurved Medical College and Postgraduate Research Center,Ashta,Sangli
🇮🇳Sangli, MAHARASHTRA, India
Dr Rupali Ranmadas Patil
Principal investigator
9225633321
rpcoolrupali@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.